CD44 and cancer: Despite the alternative splicing of CD44, targeting this receptor is an attractive strategy for developing receptor-mediated therapeutics due to the ability of a single HA chain to simultaneously bind multiple CD44 receptors and to signal numerous cancer-associated mechanisms.